Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies
Dasatinib, a second-generation tyrosine kinase inhibitor, is recommended as first-line treatment for patients newly diagnosed with chronic myeloid leukemia (CML) and second-line treatment for those who are resistant or intolerant to therapy with imatinib. Dasatinib is superior to imatinib in terms o...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1113462/full |
| _version_ | 1828041168039968768 |
|---|---|
| author | Fang Cheng Fang Cheng Qiling Xu Qiling Xu Qiang Li Qiang Li Zheng Cui Zheng Cui Weiming Li Fang Zeng Fang Zeng |
| author_facet | Fang Cheng Fang Cheng Qiling Xu Qiling Xu Qiang Li Qiang Li Zheng Cui Zheng Cui Weiming Li Fang Zeng Fang Zeng |
| author_sort | Fang Cheng |
| collection | DOAJ |
| description | Dasatinib, a second-generation tyrosine kinase inhibitor, is recommended as first-line treatment for patients newly diagnosed with chronic myeloid leukemia (CML) and second-line treatment for those who are resistant or intolerant to therapy with imatinib. Dasatinib is superior to imatinib in terms of clinical response; however, the potential pulmonary toxicities associated with dasatinib, such as pulmonary arterial hypertension and pleural effusion, may limit its clinical use. Appropriate management of dasatinib-related severe events is important for improving the quality of life and prognosis of patients with CML. This review summarizes current knowledge regarding the characteristics, potential mechanisms, and clinical management of adverse reactions occurring after treatment of CML with dasatinib. |
| first_indexed | 2024-04-10T17:05:15Z |
| format | Article |
| id | doaj.art-78f1e0bf830349fcb215d865df05424b |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T17:05:15Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-78f1e0bf830349fcb215d865df05424b2023-02-06T05:09:36ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-02-011310.3389/fonc.2023.11134621113462Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategiesFang Cheng0Fang Cheng1Qiling Xu2Qiling Xu3Qiang Li4Qiang Li5Zheng Cui6Zheng Cui7Weiming Li8Fang Zeng9Fang Zeng10Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, ChinaDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, ChinaDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, ChinaDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, ChinaDepartment of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, ChinaDasatinib, a second-generation tyrosine kinase inhibitor, is recommended as first-line treatment for patients newly diagnosed with chronic myeloid leukemia (CML) and second-line treatment for those who are resistant or intolerant to therapy with imatinib. Dasatinib is superior to imatinib in terms of clinical response; however, the potential pulmonary toxicities associated with dasatinib, such as pulmonary arterial hypertension and pleural effusion, may limit its clinical use. Appropriate management of dasatinib-related severe events is important for improving the quality of life and prognosis of patients with CML. This review summarizes current knowledge regarding the characteristics, potential mechanisms, and clinical management of adverse reactions occurring after treatment of CML with dasatinib.https://www.frontiersin.org/articles/10.3389/fonc.2023.1113462/fulldasatinibchronic myeloid leukemiaadverse reactionspharmacotherapypleural effusion |
| spellingShingle | Fang Cheng Fang Cheng Qiling Xu Qiling Xu Qiang Li Qiang Li Zheng Cui Zheng Cui Weiming Li Fang Zeng Fang Zeng Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies Frontiers in Oncology dasatinib chronic myeloid leukemia adverse reactions pharmacotherapy pleural effusion |
| title | Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies |
| title_full | Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies |
| title_fullStr | Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies |
| title_full_unstemmed | Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies |
| title_short | Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies |
| title_sort | adverse reactions after treatment with dasatinib in chronic myeloid leukemia characteristics potential mechanisms and clinical management strategies |
| topic | dasatinib chronic myeloid leukemia adverse reactions pharmacotherapy pleural effusion |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1113462/full |
| work_keys_str_mv | AT fangcheng adversereactionsaftertreatmentwithdasatinibinchronicmyeloidleukemiacharacteristicspotentialmechanismsandclinicalmanagementstrategies AT fangcheng adversereactionsaftertreatmentwithdasatinibinchronicmyeloidleukemiacharacteristicspotentialmechanismsandclinicalmanagementstrategies AT qilingxu adversereactionsaftertreatmentwithdasatinibinchronicmyeloidleukemiacharacteristicspotentialmechanismsandclinicalmanagementstrategies AT qilingxu adversereactionsaftertreatmentwithdasatinibinchronicmyeloidleukemiacharacteristicspotentialmechanismsandclinicalmanagementstrategies AT qiangli adversereactionsaftertreatmentwithdasatinibinchronicmyeloidleukemiacharacteristicspotentialmechanismsandclinicalmanagementstrategies AT qiangli adversereactionsaftertreatmentwithdasatinibinchronicmyeloidleukemiacharacteristicspotentialmechanismsandclinicalmanagementstrategies AT zhengcui adversereactionsaftertreatmentwithdasatinibinchronicmyeloidleukemiacharacteristicspotentialmechanismsandclinicalmanagementstrategies AT zhengcui adversereactionsaftertreatmentwithdasatinibinchronicmyeloidleukemiacharacteristicspotentialmechanismsandclinicalmanagementstrategies AT weimingli adversereactionsaftertreatmentwithdasatinibinchronicmyeloidleukemiacharacteristicspotentialmechanismsandclinicalmanagementstrategies AT fangzeng adversereactionsaftertreatmentwithdasatinibinchronicmyeloidleukemiacharacteristicspotentialmechanismsandclinicalmanagementstrategies AT fangzeng adversereactionsaftertreatmentwithdasatinibinchronicmyeloidleukemiacharacteristicspotentialmechanismsandclinicalmanagementstrategies |